EUCTR2011-000195-34-IT进行中（未招募）1 期
A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC).
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 501
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written, signed informed consent. 2. Age = 18 years. 3. Eastern Cooperative Oncology Group (ECOG)Performance Status of 0, 1 or 2. 4. For patients with metastatic BCC, histologic confirmation of distant BCC metastasis. 5. For patients with locally advanced BCC, at least one histologically confirmed lesion 10 mm or more in diameter and written confirmation from a surgical specialist that the tumor is considered inoperable or that surgery is contraindicated. Examples of medical contraindications to surgery include but are not limited to: • BCC that has recurred in the same location after two or more surgical procedures and curative resection is deemed unlikely. • Anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation). 6. For patients with locally advanced BCC, radiotherapy must have been previously administered for locally advanced BCC, unless radiotherapy is contraindicated or inappropriate (e.g., hypersensitivity to radiation due to genetic syndrome such as Gorlin syndrome, limitations because of location of tumor, or cumulative prior radiotherapy dose). For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation. 7. Patients with Gorlin syndrome may enroll in this study but must meet the criteria for locally advanced or metastatic disease listed above. 8. Patients with measurable and/or non-measurable disease (as defined by RECIST Version 1.1) are allowed. 9. Adequate organ function, as evidenced by the following laboratory results: • Hemoglobin > 8.5 g/dL. • Granulocyte count = 1000/µL. • Platelet count = 75,000/µL. • AST and ALT = 3 × the upper limit of normal (ULN). • Total bilirubin = 1.5 × the ULN or within 3 × the ULN for patients with documented Gilbert syndrome. 10. Fertile men and women must use two highlyeffective methods of contraception during treatment and for at least 7 months after completion of treatment as directed by their physician. Highlyeffective methods of contraception are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices), please refer to Appendix 2 for more detail. At the discretion of the investigator, acceptable methods of contraception may include total abstinence. [Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.] 11. For male patients with female partners of childbearing potential, agreement to use a condom, and to advise their female partner to use an additional method of contraception during the study and for 7 months after discontinuation of vismodegib (GDC-0449). 12. Agreement not to donate blood or blood products during the study and for at least 7 months after discontinuation of vismodegib (GDC-0449); for male patients, agreement not to donate sperm during the study and for at least 7 months after discontinuation of vismodegib (GDC-0449). 13. Life expectancy > 12 weeks. 14. Negative serum pregnancy test within 96 hours prior to commencement of dosing in premenopausal women. Women of nonchildbearing potential may be included if they are either surgically sterile or have been postmenopausal for = 1 year.
- •Are the trial su
排除标准
- •1. Inability or unwillingness to swallow capsules. 2. Pregnancy or lactation. 3. Concurrent non–protocol-specified anti-tumor therapy (e.g., chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy, including participation in an experimental drug study; note that treatment breaks up to 8 weeks for radiation therapy are allowed (see Section 6.1.1)). 4. Completion of most recent anti-tumor therapy less than 21 days prior to initiation of treatment. 5. Uncontrolled medical illnesses such as infection requiring treatment with intravenous antibiotics. 6. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk from treatment complications. 7. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. 8. Corrected QT (QTc) interval = 450 msec at baseline.
研究者
相似试验
进行中（未招募）
1 期
A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaEUCTR2011-000195-34-GBF. Hoffmann-La Roche Ltd.501
进行中（未招募）
1 期
A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaEUCTR2011-000195-34-NOF. Hoffmann-La Roche Ltd.501
进行中（未招募）
1 期
A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaEUCTR2011-000195-34-IEF. Hoffmann-La Roche Ltd.1,200
进行中（未招募）
1 期
A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinomaocally advanced or metastatic basal cell carcinoma (BCC)MedDRA version: 19.0Level: PTClassification code 10004146Term: Basal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000195-34-CZF. Hoffmann-La Roche Ltd.501
进行中（未招募）
1 期
A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaEUCTR2011-000195-34-BGF. Hoffmann-La Roche Ltd.1,200